Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
11C-Choline · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| C-Choline PET Scans | EXPERIMENTAL | Radioactive doses of 11C-Choline: 400 MBq ± 10% per injection, pre-radiation treatment and following treatment at 3 and 6 months |
| Name | Type | Description |
|---|---|---|
| 11C-Choline | RADIATION | - |
Inclusion Criteria: 1. Age ≥ 18 years 2. Biopsy proven prostate cancer with an intermediate risk feature defined as 1. Gleason score 7, PSA \<20, T1-T2C or 2. Gleason score 6, PSA 10-20, T1-T2C or 3. Gleason Score 6 or 7, PSA \<20, T2C 3. Localized disease based on staging investigations ...
11C-Choline is an investigational radiopharmaceutical being studied for use in prostatic neoplasms, or prostate cancer. It is being evaluated in a clinical trial to determine whether delivering an extra dose of radiation to areas with more cancer is better than standard treatment that gives the same radiation dose throughout the prostate gland.
11C-Choline is a radiolabeled form of choline, a natural compound that is taken up by cells. In prostate cancer, choline is incorporated into cell membranes, and its uptake is often increased in malignant tissue. This allows 11C-Choline to be used as a tracer to identify areas of more active cancer for targeted radiation.
11C-Choline is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company's stock is traded under the ticker symbol ALBT. The drug is currently in early-stage clinical development for prostate cancer.
11C-Choline is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
11C-Choline has been studied in one completed Phase 1 clinical trial, identified by the identifier NCT02004418. The trial enrolled 21 male patients with prostate cancer in Canada. It was an uncontrolled, non-randomized study that was not double-blinded, and it used biomarker selection.